Methamphetamine-Induced Loss of Striatal Dopamine Innervation in BDNF Heterozygote Mice Does Not Further Reduce D3 Receptor Concentrations

Synapse

Volumn 52, Issue 1, 2004, Pages 11-19

  Joyce, Jeffrey N ^a   Renish, Lynn ^a   Osredkar, Tracy ^a   Walro, Jon M ^b   Kucera, Jan ^c   Dluzen, Dean E ^b  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b Northeastern Ohio Medical University   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Caudate putamen; Dopamine transporter; Nucleus accumbens; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; METHAMPHETAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NEUROTOXICITY; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; TRANSGENIC MOUSE;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HETEROZYGOTE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METHAMPHETAMINE; MICE; MICE, INBRED BALB C; MICE, MUTANT STRAINS; NEOSTRIATUM; NERVE TISSUE PROTEINS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; TYROSINE 3-MONOOXYGENASE;

EID: 1542373725     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10309     Document Type: Article

References (54)

1. Allsopp TE, Kiselev S, Wyatt S, Davies AM. 1995. Role of Bcl-2 in the brain-derived neurotrophic factor survival response. Eur J Neurosci 7:1266-1272.
2. Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, Lindsay RM, Wiegand SJ. 1997. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389:856-860.
3. 3 receptor function. Nat Med 9:762-767.
4. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM. 2001. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65:135-172.
5. Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC. 1997. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 94:3363-3367.
6. Cadet JL, Brannock C. 1998. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int 32:117-131.
7. Conover JC, Erickson JT, Katz DM, Bianchi LM, Poueymirou WT, McClain J, Pan L, Helgren M, Ip NY, Boland P. 1995. Neuronal deficits, not involving motor neurons, in mice lacking BDNF and/or NT4. Nature 375:235-238.
8. Dawson NM, Hamid EH, Egan MF, Meredith GE. 2001. Changes in the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment. Synapse 39:70-81.
9. Dluzen DE, Story GM, Xu K, Kucera J, Walro JM. 1999. Alterations in nigrostriatal dopaminergic function within BDNF mutant mice. Exp Neurol 160:500-507.
10. Dluzen DE, Gao X, Story GM, Anderson LI, Kucera J, Walro JM. 2001. Evaluation of nigrostriatal dopaminergic function in adult +/+ and +/- BDNF mutant mice. Exp Neurol 170:121-128.
11. Dluzen DE, Anderson LI, McDermott JL, Kucera J, Walro JM. 2002. Striatal dopamine output is compromised within +/- BDNF mice. Synapse 43:112-117.
12. Eisch AJ, Gaffney M, Weihmuller FB, O'Dell SJ, Marshall JF. 1992. Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine. Brain Res 598:321-326.
13. Ernfors P, Lee KF, Jaenisch R. 1994. Mice lacking brain-derived neurotrophic factor develop with sensory deficits. Nature 368:147-150.
14. Florijn WJ, Tarazi FI, Creese I. 1997. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther 280:561-569.
15. Gagnon C, Gomez-Mancilla B, Markstein R, Bedard PJ, Di Paolo T. 1995. Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors. Prog Neuropsychopharmacol Biol Psychiatry 19:667-676.
16. Graham WC, Clarke CE, Boyce S, Sambrook MA, Crossman AR, Woodruff GN. 1990. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor super-sensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Res 514:103-110.
17. Gross CE, Ravenscroft P, Dovero S, Jaber M, Bioulac B, Bezard E. 2003. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice. J Neurochem 84:1246-1255.
18. 3 receptor expression and triggers behavioural sensitization. Nature 411:86-89.
19. 3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 54:225-232.
20. 3 dopamine receptor in rat nucleus accumbens and islands of Calleja. J Pharmacol Exp Ther 289:587-598.
21. Hassouna I, Wickert H, Zimmermann M, Gillardon F. 1996. Increase in bax expression in substantia nigra following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment of mice. Neurosci Lett 204:85-88.
22. Hof PR, Young WG, Bloom FE, Belichenko PV, Celio MR. 2000. Comparative cytoarchitectonic atlas of the C57/BL6 and 129/Sv mouse brains. Amsterdam: Elsevier Science.
23. Horger BA, Iyasere CA, Berhow MT, Messer CJ, Nestler EJ, Taylor JR. 1999. Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. J Neurosci 19:4110-4122.
24. Hu P, Kalb RG. 2003. BDNF heightens the sensitivity of motor neurons to excitotoxic insults through activation of TrkB. J Neurochem 84:1421-1430.
25. Hyman C, Juhasz M, Jackson C, Wright P, Ip NY, Lindsay RM. 1994. Overlapping and distinct actions of the neurotrophins BDNF, NT-3, and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. J Neurosci 14:335-347.
26. Joyce JN. 1991. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine system. Exp Neurol 113:261-276.
27. 3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period. Synapse 40:137-144.
28. 3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 90:231-259.
29. Joyce JN, Marshall JF, Bankiewicz KS, Kopin IJ, Jacobowitz DM. 1986. Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density. Brain Res 382:360-364.
30. 3 receptors with degeneration of the dopamine system. Neuroreport 11:2173-2175.
31. 2 receptors. Brain Res 955:138-152.
32. LaHoste GJ, Marshall JF. 1991. Chronic eticlopride and dopamine denervation induce equal nonadditive increases in striatal D2 receptor density: autoradiographic evidence against the dual mechanism hypothesis. Neuroscience 41:473-481.
33. Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D. 2002. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci 22:8951-8960.
34. Lévesque D, Martres MP, Diaz J, Griffon N, Lammers CH, Sokoloff P, Schwartz JC. 1995. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc Natl Acad Sci USA 92:1719-1723.
35. Levinson AJ, Garside S, Rosebush PI, Mazurek MF. 1998. Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat. Neuroscience 84:201-211.
36. Liu X, Ernfors P, Wu H, Jaenisch R. 1995. Sensory but not motor neuron deficits in mice lacking NT4 and BDNF. Nature 375:238-241.
37. Morissette M, Goulet M, Grondin R, Blanchet P, Bedard PJ, Di Paolo T, Levesque D. 1998. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur J Neurosci 10:2565-2573.
38. Muto Y, Hayashi T, Higashi Y, Endo T, Yamamoto T, Sato K. 1999. Age-related decrease in brain-derived neurotrophic factor gene expression in the brain of the zitter rat with genetic spongiform encephalopathy. Neurosci Lett 271:69-72.
39. Myers RE, Anderson LI, Dluzen DE. 2003. Estrogen, but not testosterone, attenuates methamphetamine-evoked dopamine output from superfused striatal tissue of female and male mice. Neuropharmacology 44:624-632.
40. Offen D, Beart PM, Cheung NS, Pascoe CJ, Hochman A, Gorodin S, Melamed E, Bernard R, Bernard O. 1998. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Proc Natl Acad Sci USA 95:5789-5794.
41. Pearce RK, Costa S, Jenner P, Marsden CD. 1999. Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets. J Neural Transm 106:663-683.
42. Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G. 2000. The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16:135-142.
43. 3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience 98:263-273.
44. 2 receptor is elevated in the striatum of Parkinson's disease. Mov Disord 13:788-797.
45. Schabitz WR, Sommer C, Zoder W, Kiessling M, Schwaninger M, Schwab S. 2000. Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Stroke 31:2212-2217.
46. Seiden LS, Ricaurte GA. 1987. Neurotoxicity of methamphetamine and related drugs. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press. p 359-366.
47. Seroogy KB, Lundgren KH, Tran TM, Guthrie KM, Isackson PJ, Gall CM. 1994. Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs. J Comp Neurol 342:321-334.
48. Spina MB, Squinto SP, Miller J, Lindsay RM, Hyman C. 1992. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system [see comments]. J Neurochem 59:99-106.
49. Staley JK, Mash DC. 1996. Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 16:6100-6106.
50. Tarazi FI, Florijn WJ, Creese I. 1997. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Neuroscience 78:985-996.
51. Ueda S, Aikawa M, Ishizuya-Oka A, Yamaoka S, Koibuchi N, Yoshimoto K. 2000. Age-related dopamine deficiency in the mesostriatal dopamine system of zitter mutant rats: regional fiber vulnerability in the striatum and the olfactory tubercle. Neuroscience 95:389-398.
52. Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, Przedborski S. 2001. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci USA 98:2837-2842.
53. Yamada M, Oligino T, Mata M, Goss JR, Glorioso JC, Fink DJ. 1999. Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc Natl Acad Sci USA 96:4078-4083.
54. Yang L, Matthews RT, Schulz JB, Klockgether T, Liao AW, Martinou JC, Penney JB Jr, Hyman BT, Beal MF. 1998. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice over-expressing Bcl-2. J Neurosci 18:8145-8152.